Lingxing Zeng

Lingxing Zeng

Auto-generated profile, based on publicly available information

Lingxing Zeng

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
JSJiachun Su
Jiachun Su
GWGuandi Wu
Guandi Wu
YYYing Ye
Ying Ye
JZJialiang Zhang
Jialiang Zhang
LZLingxing Zeng
Lingxing Zeng
JZJian Zheng
Jian Zheng
5-Methylcytosine (m5C) is a posttranscriptional RNA modification participating in many critical bioprocesses, but its functions in human cancer remain unclear. Here, by detecting the transcriptome-wide m5C profiling in esophageal squamous cell carcinoma (ESCC), we showed increased m5C methylation in ESCC tumors due to the overexpressed m5C methyltransferase NSUN2. Aberrant expression of NSUN2 was positively regulated by E2F Transcription Factor 1 (E2F1). High NSUN2 levels predicted poor survival of ESCC patients. Moreover, silencing NSUN2 suppressed ESCC tumorigenesis and progression in Nsun2 knockout mouse models. Mechanistically, NSUN2 induced m5C modification of growth factor receptor-bound protein 2 (GRB2) and stabilized its mRNA, which was mediated by a novel m5C mediator, protein lin-28 homolog B (LIN28B). Elevated GRB2 levels increased the activation of PI3K/AKT and ERK/MAPK signalling. These results demonstrate that NSUN2 enhances the initiation and progression of ESCC via m5C-LIN28B dependent stabilization of GRB2 transcript, providing a promising epitranscriptomic-targeted therapeutic strategy for ESCC.

7 September 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SDShuang Deng
Shuang Deng
JZJialiang Zhang
Jialiang Zhang
JSJiachun Su
Jiachun Su
ZZZhixiang Zuo
Zhixiang Zuo
LZLingxing Zeng
Lingxing Zeng
JZJian Zheng
Jian Zheng

13 November 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RLRui Li
Rui Li
HZHongzhe Zhao
Hongzhe Zhao
XHXudong Huang
Xudong Huang
JZJialiang Zhang
Jialiang Zhang
RBRuihong Bai
Ruihong Bai
JZJian Zheng
Jian Zheng

26 May 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ZCZiming Chen
Ziming Chen
YZYifan Zhou
Yifan Zhou
CXChunling Xue
Chunling Xue
LZLingxing Zeng
Lingxing Zeng
SDShuang Deng
Shuang Deng
JZJian Zheng
Jian Zheng

10 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYanfen Zheng
Yanfen Zheng
XLXingyang Li
Xingyang Li
SDShuang Deng
Shuang Deng
HZHongzhe Zhao
Hongzhe Zhao
YYYing Ye
Ying Ye
ZZZhixiang Zuo
Zhixiang Zuo
N6-methyladenosine (m6A) modification of gene transcripts plays critical roles in cancer. Here we report transcriptomic m6A profiling in 98 tissue samples from 65 individuals with pancreatic ductal adenocarcinoma (PDAC). We identify 17,996 m6A peaks with 195 hyper-methylated and 93 hypo-methylated in PDAC compared with adjacent normal tissues. The differential m6A modifications distinguish two PDAC subtypes with different prognosis outcomes. The formation of the two subtypes is driven by a newly identified m6A regulator CSTF2 that co-transcriptionally regulates m6A installation through slowing the RNA Pol II elongation rate during gene transcription. We find that most of the CSTF2-regulated m6As have positive effects on the RNA level of host genes, and CSTF2-regulated m6As are mainly recognized by IGF2BP2, an m6A reader that stabilizes mRNAs. These results provide a promising PDAC subtyping strategy and potential therapeutic targets for precision medicine of PDAC.

19 September 2023 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
GWGuandi Wu
Guandi Wu
JSJiachun Su
Jiachun Su
LZLingxing Zeng
Lingxing Zeng
SDShuang Deng
Shuang Deng
XHXudong Huang
Xudong Huang
JZJian Zheng
Jian Zheng